Metastasis free survival in older men with nonmetastatic castration-resistant prostate cancer treated with androgen receptor inhibitors: An FDA-pooled analysis.

Harpreet Singh,Lijun Zhang,Anup Amatya,Yutao Gong,Daniel L. Suzman,Chana Weinstock,Elaine Chang,Mitchell Steven Anscher,Dow-Chung Chi,James Xu,Jamie Renee Brewer,Sundeep Agrawal,Michael Holman Brave,Mehrnoosh Hadadi,Marc Robert Theoret,Paul G. Kluetz,Amna Ibrahim,Richard Pazdur,Julia A. Beaver

Metastasis free survival in older men with nonmetastatic castration-resistant prostate cancer treated with androgen receptor inhibitors: An FDA-pooled analysis.

2020

Harpreet Singh
Lijun Zhang
Anup Amatya
Yutao Gong
Daniel L. Suzman
Chana Weinstock
Elaine Chang
Mitchell Steven Anscher
Dow-Chung Chi
James Xu
Jamie Renee Brewer
Sundeep Agrawal
Michael Holman Brave
Mehrnoosh Hadadi
Marc Robert Theoret
Paul G. Kluetz
Amna Ibrahim
Richard Pazdur
Julia A. Beaver

12038Background: The FDA has approved three androgen receptor (AR) inhibitors for nonmetastatic castration-resistant prostate cancer (nmCRPC) based on improvements in metastasis-free survival (MFS)...

Keywords:

metastasis free survival
Oncology
pooled analysis
Internal medicine
Pathology
castration resistant
Prostate cancer
Medicine
Androgen receptor

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations